Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC

Summary

This study was planned to determine if neoadjuvant capmatinib could improve the major pathological response (MPR) in patients with Stage IB-IIIA, N2 and selected IIIB (T3N2 or T4N2) lung cancers with Mesenchymal Epithelial Transition (MET) exon 14 mutations and/or high MET amplification beyond those achieved with surgery, chemotherapy, and radiation. Treatment was to be continued with capmatinib in the adjuvant setting to evaluate the potential clinical benefit of extended therapy. The purpose of this study is to determine if neoadjuvant capmatinib can improve outcomes in participants with stages I-IIIA non-small cell lung cancer with MET exon 14 mutations and/or high MET amplification beyond those achieved with surgery, chemotherapy, and radiation.

Timeline

Start

2022-08-10

Primary completion

2024-03-13

Completion

2024-03-13

Outcome

Outcome not reported

Stopped (Enrollment): “The study was terminated early due to recruitment challenges.”

Drugs

Indications